Health Canada Santé Canada

Evaluation Report for Category B, Subcategories 2.3, 2.5 Application

Application Number: 2019-5870
Application: New End-use Product (Product Chemistry) - Identity of Formulants, Formulation Type
Product: Brigand WB
Registration Number: 34077
Active ingredient (a.i.): Bromadiolone
PMRA Document Number: 3209980

Purpose of Application

The purpose of this application was to register a wax-based rodenticide block bait for control of Norway (brown) rats, roof rats and house mice within structures or outside, around perimeter fencing.

Chemistry Assessment

Brigand WB is formulated as a solid wax block containing bromadiolone at a concentration of 0.005%. This end-use product has a density of 1.17 g/mL. The required chemistry data for Brigand WB have been provided, reviewed and found to be acceptable.

Health Assessments

Brigand WB is of low acute toxicity via the oral and dermal routes of exposure. It is minimally irritating to the eyes and non-irritating to the skin. It is not expected to cause an allergic skin reaction. Exposure via the inhalation route is not expected.

Worker exposures to bromadiolone are not expected to exceed those of registered products. No health risks of concern are expected, provided workers wear the appropriate personal protective equipment and follow all label directions. No health risks of concern are expected for the public.

A dietary risk assessment was not required for this application.

Environmental Assessment

Brigand WB and the previously registered wax-based rodenticide block bait end-use product, Brigand SB, contain the same concentration of the active ingredient bromadiolone (0.005% of bromadiolone). As such, no additional environmental risk is expected from the use of this new commercial class end-use product. Environmental concerns are addressed in the environmental label statements.

Canada

Value Assessment

Results from four operational trials supported the use of Brigand WB to control Norway (brown) rats, roof rats and house mice. Trials showed that Brigand WB reduced post-treatment Norway rat and house mouse feeding by 99.3-100% and animal tracks by 96-100% in moderately to highly infested areas with known warfarin-resistant rodent populations. The data on Norway rats were extrapolated to roof rats because of similarity in biology.

Rodent infestations degrade commercial structures and buildings, spoil food stores and may create health risks for humans and livestock. Brigand WB provides an effective rodenticide that can be used to combat warfarin-resistant rodent populations found in the indoor and outdoor areas of residential, commercial, industrial, agricultural, public buildings and port or terminal buildings.

Conclusion

The Pest Management Regulatory Agency has completed an assessment of the information provided, and has found it sufficient to support the registration of Brigand WB.

References

PMRA Document Number	Reference
3046924	1999, 96021264 Storage Stability of Rodex Wax Blocks, DACO: 3.5, 3.5.10, 3.5.2, 3.5.3, 3.5.4 CBI
3046935	2005, Analytical test method ch-350-2005 Rodex Wax Block Bait, DACO: 3.4.1 CBI
3046936	2019, Method of manufacture - bromadiolone wax blocks 9-24-19, DACO: 3.2, 3.2.1,3.2.2 CBI
3068494	2008, 2254-0039 Rodex Wax Block Bait - Determination of Physico-Chemical Properties, DACO: 3.5.11,3.5.2,3.5.3,3.5.6
3068495	2019, AEWL1983 - CAN Brigand WB DACO 3.5 data, DACO: 3.5.12, 3.5.13, 3.5.14, 3.5.15, 3.5.7, 3.5.8, 3.5.9
3162231	2006, ch-350-2005 Final Report - Rodex Wax Block Bait - Analytical Method 2006, DACO: 3.4.1
3162232	2020, Method of manufacture - bromadiolone wax blocks, DACO: 3.2,3.2.1,3.2.2 CBI
3046925	2007, 2254-0033 Bromadiolone Wax Block - Acute Oral Toxicity in the Rat - Fixed Dose Method, DACO: 4.6.1 CBI
3046926	2007, 2254-0034 Bromadiolone Wax Block - Acute Dermal Toxicity (Limit Test) in the Rat, DACO: 4.6.2 CBI
3046927	2007, 2254-0035 Bromadiolone Wax Block - Acute Irritation in the Rabbit, DACO: 4.6.5 CBI
3046928	2007, 2254-0036 Bromadiolone Wax Block - Acute Eye Irritation in the Rabbit, DACO: 4.6.4 CBI
3105301	2020, AEWL2035 CA Inhalation Waiver, DACO: 4.6.3
3105302	2020, AEWL2036 CA Sensitisation Waiver, DACO: 4.6.6
3046922	2019. Brigand WB - Use Description/Scenario: DACO5.2
3046930	2004, PEL-001-04 field trial Bromadiolone block - mice #1, DACO: 10.2,10.2.3,10.2.3.3
3046931	2004, PEL-002-04 field trial Bromadiolone block - mice #2, DACO: 10.2,10.2.3,10.2.3.3
3046932	2004, PEL-003-04 field trial Bromadiolone block - rats #1, DACO: 10.2,10.2.3,10.2.3.3
3046933	2004, PEL-008-04 field trial Bromadiolone block - rats #2, DACO: 10.2,10.2.3,10.2.3.3
3135065	2004, pel-001-04 Field Trial Report - Rodex Wax Block Bait, House Mice, DACO: 10.2,10.2.3
3135066	2004, pel-002-04 Field Trial Report - Rodex Wax Block Bait, House Mice, DACO: 10.2,10.2.3
3135067	2004, pel-003-04 Field Trial Report - Rodex Wax Block Bait, Brown Rats, DACO: 10.2,10.2.3

3135068	2004, pel-008-04 Field Trial Report - Rodex Wax Block Bait, Brown Rats, DACO: 10.2,10.2.3
3135069	2020, Comparison of Formulations Used in Efficacy with the Current Rodex, DACO: 10.6